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Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases 
and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiff-
ness reduction is associated with an improvement in survival. Reduction of arterial stiffness by 
pharmacological drugs varies according to the drugs and doses used and duration of treatment. 
This effect on the arteries differs among the various classes of drugs and among individual drugs 
in the same class. Quantiﬁ  cation of the stiffness and other properties of the arterial wall can be 
used to monitor the responses to therapy in individuals with hypertension and other cardiovas-
cular diseases. These measures can then be used as surrogate markers for the risk of clinical 
events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease 
in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective 
effects of RAS inhibition are partly independent from blood pressure reduction and related to 
several mechanisms including vascular protective effects. The aim of the TRanscend Arterial 
stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), 
telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized 
Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) 
trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo 
controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some 
clinical baseline data of the TRANS substudy are reported. When completed, the results of the 
TRANS substudy will show whether the beneﬁ  cial effects of treatment with telmisartan on 
cardiovascular outcome may be related to an improvement in arterial stiffness.
Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, 
antihypertensive
Introduction
The degree of arterial stiffness, obtained in various populations, has been found to be 
a powerful independent marker of vascular target organ damage and an independent 
prognostic predictor for cardiovascular morbidity, as well as cardiovascular and all-
cause mortality (Blacher et al 1999; Laurent et al 2001, 2003; Meaume et al 2001; 
Boutouyrie et al 2002; Cruickshank et al 2002; Dernellis et al 2005; Shokawa et al 
2005; Sutton-Tyrrell et al 2005; Mattace-Raso et al 2006; Willum-Hansen et al 2006). 
Measuring pulse wave velocity (PWV) to assess arterial stiffness is a simple and 
reproducible method. The underlying principles and technique of this method have been 
described in detail previously (Asmar 1999). Several experimental studies have shown 
that PWV is related to the arterial wall structure, function, geometry and endothelium 
functions (Asmar 1999). Validation studies have shown that automatic measurements 
of PWV are simple, non-invasive, accurate, and reproducible (Asmar et al 1995; Van 
Bortel et al 2002; Laurent et al 2006), making this technique a convenient, sensitive 
and useful tool in physiological and pharmacological studies.Vascular Health and Risk Management 2007:3(4) 382
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Basic pharmacological concepts 
of arterial stiffness
Several important points serve to better understand the effects 
of pharmacological intervention on arterial stiffness.
The arterial site
Atherosclerosis, arterial abnormalities, and their progression 
vary in different arterial sites. Arteries are heterogenous in 
structure and the arterial site has to be considered in assess-
ment of the pharmacological treatment (Asmar 1999). The 
impact of a given pharmacological agent may differ on the 
various components of the arterial wall (elastin, collagen, 
muscle) according to its pharmacodynamic properties. It 
is logical to assume that the arterial effects of a given drug 
administered at a given dose and period of time may differ 
according to the arterial site, which may be more elastic (aorta, 
carotid) or more muscular (radial) arteries (Topouchian et al 
1999). Figure 1 shows an example of the different effects on 
the arterial sites produced by the same antihypertensive drug 
in the same patients (Asmar 1999; Topouchian et al 1999).
Duration of treatment 
Since several mechanisms may be involved in producing 
reductions in arterial stiffness with a given treatment, 
assessment of arterial stiffness has to distinguish between the 
effects of acute, short-term, or long-term chronic treatments. 
For example, after acute administration of an antihyperten-
sive drug, improvement of arterial stiffness is principally 
related to functional or mechanical mechanisms such as 
reduction of distension pressure, reduction of smooth muscle 
tone, enhancement of endothelial functions, whereas after 
long-term chronic treatment, additional mechanisms can be 
involved, eg, changes in the arterial geometry and structure, 
reduction in degree of ﬁ  brosis, increase in elastin/collagen 
ratio, remodeling of the arterial wall (Asmar 1999; Laurent 
et al 2002). Experts agree that assessment of arterial stiff-
ness after a long-term treatment period should be preferred 
because of the underlying pathophysiological mechanisms 
involved and because acute effects may not predict long-
term efﬁ  cacy. 
Drug doses 
In assessing the efﬁ  cacy of a drug, one needs to consider 
the dose/effect relationship. This relationship may differ 
from other properties of the drug such as the dose/effect of 
its antihypertensive properties (Asmar 1999; Laurent et al 
2002). A clear dissociation between the antihypertensive 
effect and the reduction of arterial stiffness by angiotensin 
converting enzyme (ACE) inhibitors has been reported. 
There is evidence that the effect on arterial wall properties 
can be seen at higher doses of ACE inhibitors than with the 










































Figure 1 Change in arterial distensibility after antihypertensive treatment in three arterial sites: abdominal aorta, carotid artery and brachial artery. Signiﬁ  cant site effect 
was observed:
  Carotid artery    Brachial artery    Abdominal aorta
  °  Before: 1.6 ± 0.7    °  Before: 0.7 ± 0.3  °  Before: 0.9 ± 0.3
  °  After: 2.2 ± 0.8    °  After: 1.3 ± 0.6  °  After: 1.3 ± 0.3
(Derived from Topouchian et al 1999)Vascular Health and Risk Management 2007:3(4) 383
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hypertensive patients (Asmar et al 1992a, b). These ﬁ  ndings, 
independent of the drug effects on BP, have been recently 
conﬁ  rmed by the results of large clinical studies on patients 
at high cardiovascular risk. In these studies, positive results 
on arterial stiffness have been observed with high doses of 
ACE inhibitors (Yusuf et al 2000; PROGRESS Collaborative 
Group 2001; Fox et al 2003).
Effect of antihypertensive agents 
on arterial stiffness
Several pharmacological studies have evaluated the effects 
of antihypertensive drugs on arterial stiffness. Table 1 shows 
the effects on PWV of different antihypertensive drug classes, 
administered double blind, either short-term (<28 days) or 
long-term (28 days) (Asmar 1999; Asmar et al 2002; Rajzer 
et al 2003; White et al 2003; Handbook of Hypertension 2006). 
During long-term treatment, improvements in central and pe-
ripheral arterial stiffness have been found with ACE inhibitors. 
Less marked improvement has been reported with angiotensin II 
receptor blockers. Beta-blockers have exhibited variable results 
according to the particular drugs used. With calcium channel 
blockers, the results are more complex. At the aortic level, all 
calcium channel blockers have shown a signiﬁ  cant reduction in 
arterial stiffness, in parallel with BP reduction, but at the periph-
eral level, arterial stiffness reduction was less evident. Diuretics 
have shown no signiﬁ  cant effects. Therefore, antihypertensive 
treatment is associated with variable effects on arterial stiffness, 
due not only to BP reduction but also duration of treatment. More 
speciﬁ  c long-term studies are needed.
Arterial stiffness or distensibility, evaluated by PWV 
or other measurements, depends on BP level. Therefore, 
any blood pressure decrease (decrease of the distension 
pressure) is theoretically associated with a decrease of 
PWV. For this reason, analysis of PWV changes according 
to BP change is important. Different situations have been 
described in the literature (Asmar 1999), the most frequent 
of which are: 
-  decrease of PWV and BP
-  decrease of PWV and small changes of BP (this may 
reﬂ  ect an independent arterial effect of the drug)
-  decrease of BP with unchanged PWV. This may reﬂ  ect 
a relatively “harmful” impact on the arterial wall by 
other mechanisms such as increasing sympathetic tone 
(hydralazine) or heart rate, or other mechanisms related 
to the impact of the drug concerned.
Taking into consideration these aspects, analysis of 
PWV changes should be discussed according to other 
hemodynamic changes such as BP, heart rate, and peripheral 
resistance.
Future perspectives
Activation of the renin-angiotensin system (RAS) has 
been implicated in the pathogenesis of a wide variety of 
diseases affecting the cardiovascular system. Clinical trials 
have shown that inhibition of the RAS, particularly by 
ACE inhibitors, is associated with important decreases in 
cardiovascular risk in a broad range of patients (Yusuf et al 
2000; PROGRESS Collaborative Group 2001; Fox et al 
2003; HOPE/HOPE-TOO Study Investigators 2005). More 
recently, angiotensin II receptor blockers (ARBs) have 
been reported to reduce cardiovascular events in different 
populations, such as patients with diabetes, hypertension, 
or heart failure (Lacourcière et al 1998; Neutel et al 1998; 
Dalhöf et al 2002; Young et al 2004). Both pathophysiologi-
cal studies and clinical trials support the hypothesis that the 
protective effects of RAS inhibition observed with ACE 
inhibitors and ARBs are, at least partly, independent from 
their blood-pressure-lowering effects. Consistent improve-
ment in arterial stiffness seems to be observed with some 
classes of drugs that target the RAS. Whether this effect on 
arterial stiffness may be observed with other drugs, such as 
ARBs, in different populations needs clariﬁ  cation.
There are several observations regarding ACE inhibitors 
(eg, adverse effects and lack of full RAS blockade during 
Table 1 Effects of antihypertensive drugs on pulse wave velocity 
  Short term treatment <28 days  Long term treatment 28 days
 Aorta  Arm/Leg  Aorta  Arm/Leg
Vasodilators      
Beta-blockers  Ì /    Ì /   Ì / 
Diuretics      / Ì  
Calcium antagonists     Ì  Ì / 
ACE inhibitors  Ì  Ì  Ì  Ì
ARBs  Ì  Ì   / Ì 
Abbreviations:  ACE, angiotensin converting enzymes;  ARB, angiotensin II receptor blockerVascular Health and Risk Management 2007:3(4) 384
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chronic treatment) and ARBs (powerful blocking effect 
on angiotensin II receptors) that can be discussed. While 
the relationship between reduction in arterial stiffness and 
decreased cardiovascular risk has been shown with ACE 
inhibitors, this relationship is not clear with ARBs. Thus, it 
is important to assess the arterial effect of ARBs after long-
term chronic treatment in high risk patients. 
Telmisartan is an ARB with a speciﬁ  c pharmacokinetic 
proﬁ  le (Lacourcière et al 1998; Neutel et al 1998). Several 
studies have investigated the effects of telmisartan on end-
organ damage and demonstrated beneﬁ  cial results. Results 
of a pilot crossover, placebo-controlled study showed that 
telmisartan reduced arterial stiffness in hypertensive patients 
with type 2 diabetes (Asmar et al 2002). The TRANSCEND 
study (Telmisartan Randomized AssessmeNt Study in ACE 
iNtolerant subjects with cardiovascular Disease) seeks to 
determine whether the ARB, telmisartan, is superior to 
placebo in high risk patients who are intolerant to ACE inhibi-
tors, in reducing the risk of cardiovascular death, myocardial 
infarction, stroke, and hospitalization for heart failure. Details 
of the TRANSCEND trial have been published previously 
elsewhere (Lacourcière et al 1998; Neutel et al 1998; Teo 
et al 2004; Asmar 2006). The TRanscend Arterial stiffNess 
Substudy (TRANS) is designed to determine the effect of 
telmisartan on arterial stiffness. This will assess whether 
the expected results of the TRANSCEND trial might be 
explained by the vascular protective effects of telmisartan and 
estimate whether the efﬁ  cacy of telmisartan on cardiovascular 




The TRANSCEND study was an international, multicenter, 
randomized, double-blind, placebo-controlled clinical 
trial (Teo et al 2004). The primary objective of the TRAN-
SCEND study was to determine if telmisartan 80 mg daily 
was superior to placebo in reducing the composite endpoint 
of cardiovascular death, myocardial infarction, stroke, or 
hospitalization for heart failure. In this substudy (TRANS), 
assessment of arterial stiffness was performed initially dur-
ing the run-in period before randomization, after 6 months 
of randomized treatment and yearly for 3 years. The primary 
objective of the TRANS study was to investigate whether 
the lower incidence of cardiovascular events with telmisartan 
was correlated with an improvement in arterial stiffness. 
Secondary objectives were to compare early changes in 
arterial stiffness between the treatment groups, to estimate 
the prognostic factors relating to changes in arterial stiffness, 
and to determine if an early change in arterial stiffness might 
be a prognostic factor for cardiovascular events.
Patients
Patient eligibility, inclusion, and exclusion criteria of the 
TRANSCEND study have been described elsewhere (Teo 
et al 2004). Approximately 6000 high risk patients were 
enrolled. 
Speciﬁ  c non-inclusion criteria for the TRANS study were: 
known signiﬁ  cant peripheral vascular disease with proximal 
artery stenosis or limb amputation, history of vascular sur-
gery at the level of the carotid artery, femoral artery, or on 
the aorta, body mass index >40 kg/m², and atrial ﬁ  brillation. 
The purpose of these additional exclusion criteria was to 
avoid conditions that may impair the quality and reliability 
of PWV measurements.
Assessment of arterial stiffness
The Complior® device (Artech Medical, Paris, France) was 
used to record PWV in this study because of its reproduc-
ibility (Asmar 1999) and simplicity of use. These properties 
were important in this large international multicenter study, 
with many sites obtaining recordings and a centralized 
assessment in a core-laboratory (Asmar et al 2001). This 
device also allowed a valid measurement of the velocity of the 
same pulse wave recorded simultaneously in different sites 
of the arterial tree. Basic principles of PWV measurements 
have been described elsewhere (Asmar 1999). The pressure 
pulse generated by ventricular ejection is propagated along 
the arterial tree at a speed determined by the geometric and 
elastic properties of the arterial wall. PWV is calculated from 
measurements of pulse transit time and the distance traveled 
by the pulse between two recording sites, according to the 
following formula: PWV (m/s) = distance (m)/transit time (s). 
All measurements are recorded on the right side of the body 
with the patient lying at ease in the supine position. 
Blood pressure measurement
Blood pressure (BP) was measured before PWV recording 
and according to standard published guidelines (O’Brien 
et al 2005). In order to minimize its variability the follow-
ing recommendations were followed: patients in supine 
position, their arms bared, and supported at heart level. 
Patients refrained from smoking or ingesting caffeine during 
the 30 minutes preceding the measurement. Measurements 
began after at least 5 minutes of rest. The appropriate cuff 
size was used to ensure accurate measurement. Vascular Health and Risk Management 2007:3(4) 385
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Logistics and organization
A total of 34 centers (from 12 countries) were selected; all were 
provided with Complior devices. All investigators participated 
in speciﬁ  c training sessions on PWV assessment organized by 
the study core laboratory. In order to limit inter-center vari-
ability of the PWV measurements, and to ensure data homo-
geneity, a pre-study assessment was carried out as part of the 
investigators’ certiﬁ  cation to participate in the study. 
Data analysis
Demographic and baseline characteristics
Demographic and baseline characteristics, risk factors, and 
relevant clinical variables (eg, cardiovascular history and 
medication), current status of diabetes, current medical 
conditions, and concurrent medications were summarized 
by treatment group and overall inclusion.
Efﬁ  cacy analysis
Primary efﬁ  cacy criterion
The primary efﬁ  cacy parameter was the change from baseline, 
after 3 years of treatment, in the aortic stiffness as assessed by 
carotid-femoral PWV. The change from baseline was deﬁ  ned 
as the mean value at the end of the treatment period minus the 
mean value at baseline. The change from baseline was compared 
between the treatment groups using a t-test. If the data did not 
conform to the assumptions of normality, then a non-parametric 
test was used. Multiple regression analysis was used to explore 
BP changes and baseline characteristics. The same analysis was 
performed with the change from baseline after 6 months of treat-
ment. In a second step, repeated measures of analysis of variance 
with PWV at 6 months, 1 year, 2 years and 3 years of treatment 
and between treatment groups was performed.
Secondary efﬁ  cacy criteria
Regression analyses were performed to estimate factors 
related to carotid-femoral PWV at baseline. Only known 
factors or factors signiﬁ  cantly related to PWV in simple 
regression analysis were included in a stepwise selection 
multiple regression analysis. If the treatment effect on PWV 
was not constant throughout the trial, regression analyses 
were performed for changes after 6 months of treatment and 
for changes between 2 and 3 years of treatment. 
Results
Logistics and organization
Among the centers participating in the TRANSCEND trial, 
34 centers from 12 countries participated in the TRANS 
study. All of these centers were provided with Complior 
devices. Investigators from all centers participated in speciﬁ  c 
training sessions and received their certiﬁ  cation by the end of 
2003. Twenty-six of the 34 centers participated actively by 
including patients in the TRANS study. Table 2 shows the 
numbers of centers and patients enrolled per center. 
Study population
Recruitment for the TRANS study took place from Novem-
ber 2003 to June 2004. During this period 296 patients from 
26 centers were enrolled. Table 2 shows their geographic 
distribution. At randomization, 17 patients were excluded 
because their PWV recordings were judged (n = 17) to be of 
insufﬁ  cient quality by the PWV Core laboratory. Therefore a 
total of 279 patients were included in the TRANS study. Their 
main baseline clinical characteristics are shown in Table 3. 
The mean values of arterial hemodynamic parameters 
of the study population remained within the upper limit 
of normal values both for blood pressure (139/80 mmHg) 
Table 2 TRANS investigating centers distribution and number of 
patients enrolled
Countries  Number of   Number of 
 centers  patients  enrolled
Belgium 2  18
China 5  100
Czech Republic  5  75
Greece 3  16
Ireland 1  2
Malaysia 1  11
Netherlands 1  2
Portugal 1  3
South Africa  2  12
Sweden 1  5
Ukraine 4  52
Total   26  296
Table 3 Baseline clinical characteristics of the TRANS study 
population 
N = 279  Mean ± SD  Range
Age (years)  67 ± 7  43–88 
Gender    M: 160 (57.3%)
    F: 119 (42.6%) 
Height (cm)  166 ± 9  140–191 
Weight (kg)  77 ± 13  41–123 
Systolic BP (mmHg)  139 ± 17  95–200 
Diastolic BP (mmHg)  80 ± 10   51–112 
Heart rate (beat/min)  66 ± 11  45–111 
Carotid-femoral PWV (m/s)  10.0 ± 2.6  4.7–21.4
Carotid-radial PWV (m/s)  9.1 ± 1.4  5.3–13.6 
Abbreviations: BP, blood pressure; PWV, pulse wave velocity.Vascular Health and Risk Management 2007:3(4) 386
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and pulse wave velocity (carotid-femoral = 10.0 ± 2.6 m/s; 
carotid-radial = 9.1 ± 1.4 m/s). These relatively “normal” 
values may be related to the baseline treatments received by 
this population at high cardiovascular risk.
Tables 4 and 5 show that patients included in the 
TRANS sub-study are at high cardiovascular risk, as 
intended for the TRANSCEND study. Results show that 
about 68% of patients had previous coronary artery dis-
ease, more than 30% had experienced previous stroke, 
13% had high-risk diabetes with evidence of end organ 
damage and about 4% experienced recent Transient 
Ischemic Attacks (TIA). Details of biochemical results 
are shown in Table 5.
Conclusion
The TRANS arterial stiffness sub-study of the TRANSCEND 
trial assessed the effect of telmisartan on arterial stiffness 
in patients at high cardiovascular risk. The results of this 
sub-study should be helpful in the interpretation of the 
results of both the TRANSCEND and the parallel ONgo-
ing Telmisartan Alone and in combination with Ramipril 
Global Endpoint Trial (ONTARGET) trials. In fact, among 
the several mechanisms supporting the cardioprotective 
effects of RAS inhibition, improvement of arterial stiffness 
is of major importance. Moreover, the TRANS substudy 
will provide information about direct assessment of the 
arterial wall which constitutes the major target and the site 
of treatment of cardiovascular disease.
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